Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

(1) Background: The oncology field has drastically changed with the advent of precision
medicine, led by the discovery of druggable genes or immune targets assessed through next …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …

Importance Biomarker testing for driver mutations is essential for selecting appropriate non–
small cell lung cancer (NSCLC) treatment but is insufficient. Objective To investigate the …

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review
on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC …

Simple Summary Liquid biopsy has recently been introduced as a novel method in cancer
diagnostics. It is less invasive for patients than conventional tissue biopsies, as the assay …